What is the most appropriate iron supplementation for a woman with severe pulmonary hypertension and iron deficiency (non‑anemic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intravenous Iron is Preferred for Pulmonary Hypertension with Iron Deficiency

For a woman with severe pulmonary hypertension and non-anemic iron deficiency, intravenous iron (specifically ferric carboxymaltose) is the superior choice over oral supplementation. 1

Rationale for IV Iron Over Oral Supplementation

The 2015 ESC/ERS guidelines explicitly state that iron substitution should be considered in PAH patients with iron deficiency, and importantly note that "oral iron absorption is impaired in patients with PAH, so i.v. iron administration may be preferable" 1. This recommendation is based on the pathophysiology of iron metabolism in PAH patients.

Why Oral Iron Fails in PAH

Research demonstrates that PAH patients have significantly reduced gastrointestinal iron uptake compared to healthy controls - with plasma iron increases of only 71.5-86.0 µg/dl versus 154.1 µg/dl in controls after oral iron administration 2. This impaired absorption occurs regardless of whether patients have chronic iron deficiency, suggesting that factors beyond iron stores (such as elevated hepcidin levels and chronic inflammation) fundamentally block oral iron absorption in this population 2.

Specific IV Iron Formulation Recommendation

Ferric carboxymaltose (FCM) is the most extensively studied and recommended IV iron formulation for PAH patients. 3

Evidence Supporting FCM:

  • Long-term efficacy: A single FCM infusion (500-1000 mg) produces immediate and sustained improvement in iron status for up to 18 months 3
  • Clinical benefits: FCM improves:
    • 6-minute walk distance (377.5m to 412.5m at 6 months, p<0.05) 3
    • WHO functional class 3
    • ESC/ERS risk status 3
    • Hospitalization rates for worsening PAH 3
  • Safety profile: Well-tolerated with no severe adverse events reported 3

Practical Administration Approach

Dosing Strategy:

  • Initial dose: 500-1000 mg FCM as a single infusion 3
  • Monitor iron indices regularly 1
  • Approximately 24% of patients may require a second infusion after ~9-10 months due to recurrent iron deficiency 3

Pre-Administration Assessment:

According to the 2024 expert consensus on IV iron administration 4, practitioners should:

  • Perform pre-infusion risk assessment for infusion reactions
  • Understand that true anaphylaxis is exceedingly rare (<1:200,000 administrations) 4
  • Recognize that most reactions are complement-activated related pseudo-allergy (CARPA/Fishbane reactions), not true allergic reactions 4
  • Monitor for treatment-emergent hypophosphatemia post-infusion 4

Critical Pitfalls to Avoid

Do not use oral iron as first-line therapy in PAH patients, even if they are non-anemic. The impaired absorption makes oral supplementation ineffective and delays appropriate treatment 1, 2. While newer oral formulations like ferrous maltol may have better bioavailability, the evidence in PAH specifically supports IV iron 5.

Do not wait for anemia to develop before treating iron deficiency. Iron deficiency without anemia is independently associated with reduced exercise capacity, compromised right ventricular function, and potentially higher mortality in PAH 1, 6.

Monitoring Parameters

After FCM administration, track:

  • Serum iron, ferritin, and transferrin saturation 3
  • Exercise capacity (6-minute walk distance) 3
  • WHO functional class 3
  • Phosphate levels (for treatment-emergent hypophosphatemia) 4

The evidence consistently demonstrates that IV iron supplementation, particularly with ferric carboxymaltose, addresses both the pathophysiologic iron absorption defect and improves clinically meaningful outcomes in PAH patients with iron deficiency 1, 3, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.